# Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing

> **NCT01730118** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 33 (actual)

## Conditions studied

- Breast Neoplasms
- Breast Cancer
- Adenocarcinomas
- Metastatic Solid Tumors Characterized by HER2/Neu Expression

## Interventions

- **BIOLOGICAL:** Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine

## Key facts

- **NCT ID:** NCT01730118
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-04
- **Primary completion:** 2019-12-03
- **Final completion:** 2019-12-03
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2022-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01730118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01730118, "Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01730118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*